Literature DB >> 11013216

MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis.

G Ganguli1, J Abecassis, B Wasylyk.   

Abstract

The MDM2 oncogene is overexpressed in 5-10% of human tumours. Its major physiological role is to inhibit the tumour suppressor p53. However, MDM2 has p53-independent effects on differentiation and does not predispose to tumorigenesis when it is expressed in the granular layer of the epidermis. These unexpected properties of MDM2 could be tissue specific or could depend on the differentiation state of the cells. Strikingly, we found that MDM2 has p53-dependent effects on differentiation, proliferation and apoptosis when it is expressed in the less differentiated basal layer cells. MDM2 inhibits UV induction of p53, the cell cycle inhibitor p21(WAF1/CIP1) and apoptosis ('sunburn cells'). Importantly, MDM2 increases papilloma formation induced by chemical carcinogenesis and predisposes to the appearance of premalignant lesions and squamous cell carcinomas. p53 has a natural role in the protection against UV damage in the basal layer of the epidermis. Our results show that MDM2 predisposes to tumorigenesis when expressed at an early stage of differentiation, and provide a mouse model of MDM2 tumorigenesis relevant to p53's tumour suppressor functions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11013216      PMCID: PMC302089          DOI: 10.1093/emboj/19.19.5135

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  80 in total

Review 1.  The mdm2 proto-oncogene.

Authors:  D S Haines
Journal:  Leuk Lymphoma       Date:  1997-07

2.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.

Authors:  R Honda; H Tanaka; H Yasuda
Journal:  FEBS Lett       Date:  1997-12-22       Impact factor: 4.124

Review 3.  Involvement of p53 in cell differentiation and development.

Authors:  N Almog; V Rotter
Journal:  Biochim Biophys Acta       Date:  1997-08-08

Review 4.  The epidermal keratinocyte as a model for the study of gene regulation and cell differentiation.

Authors:  R L Eckert; J F Crish; N A Robinson
Journal:  Physiol Rev       Date:  1997-04       Impact factor: 37.312

5.  Targeted expression of activated erbB-2 to the epidermis of transgenic mice elicits striking developmental abnormalities in the epidermis and hair follicles.

Authors:  W Xie; X Wu; L T Chow; E Chin; A J Paterson; J E Kudlow
Journal:  Cell Growth Differ       Date:  1998-04

6.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

7.  Mdm2 promotes the rapid degradation of p53.

Authors:  Y Haupt; R Maya; A Kazaz; M Oren
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

Review 8.  Mdm2: keeping p53 under control.

Authors:  J Piette; H Neel; V Maréchal
Journal:  Oncogene       Date:  1997-08-28       Impact factor: 9.867

9.  Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.

Authors:  J Roth; M Dobbelstein; D A Freedman; T Shenk; A J Levine
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

10.  Basal cell carcinomas in mice overexpressing sonic hedgehog.

Authors:  A E Oro; K M Higgins; Z Hu; J M Bonifas; E H Epstein; M P Scott
Journal:  Science       Date:  1997-05-02       Impact factor: 47.728

View more
  18 in total

1.  The tumor suppressor p53 inhibits Net, an effector of Ras/extracellular signal-regulated kinase signaling.

Authors:  Koji Nakade; Hong Zheng; Gitali Ganguli; Gilles Buchwalter; Christian Gross; Bohdan Wasylyk
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

Review 2.  Keratinocyte apoptosis in epidermal development and disease.

Authors:  Deepak Raj; Douglas E Brash; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2006-02       Impact factor: 8.551

3.  Alterations in MDM2 expression in esophageal squamous cell carcinoma: relationship with p53 status.

Authors:  S Arora; R Mathew; M Mathur; T K Chattopadhayay; R Ralhan
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

4.  Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.

Authors:  Sarah De Clercq; Agnieszka Gembarska; Geertrui Denecker; Marion Maetens; Michael Naessens; Katharina Haigh; Jody J Haigh; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2010-09-20       Impact factor: 4.272

5.  Regulation of Notch1 gene expression by p53 in epithelial cells.

Authors:  Takashi Yugawa; Keisuke Handa; Mako Narisawa-Saito; Shin-ichi Ohno; Masatoshi Fujita; Tohru Kiyono
Journal:  Mol Cell Biol       Date:  2007-03-12       Impact factor: 4.272

6.  Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53.

Authors:  D Grossman; P J Kim; O P Blanc-Brude; D E Brash; S Tognin; P C Marchisio; D C Altieri
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

7.  p53 and MDM2 protein expression in actinic cheilitis.

Authors:  Maria da Conceição Andrade de Freitas; Luciana Maria Pedreira Ramalho; Flávia Caló Aquino Xavier; André Luis Gomes Moreira; Sílvia Regina Almeida Reis
Journal:  J Appl Oral Sci       Date:  2008 Nov-Dec       Impact factor: 2.698

Review 8.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Authors:  Sanjeev Shangary; Shaomeng Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

9.  Expression of COUP-TF-interacting protein 2 (CTIP2) in human atopic dermatitis and allergic contact dermatitis skin.

Authors:  Gitali Ganguli-Indra; Xiaobo Liang; Stephen Hyter; Mark Leid; Jon Hanifin; Arup K Indra
Journal:  Exp Dermatol       Date:  2009-03-29       Impact factor: 3.960

Review 10.  Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.

Authors:  Qin Li; Guillermina Lozano
Journal:  Clin Cancer Res       Date:  2012-12-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.